-transparent.png){kind=logo}
We report here the results of our evaluation of virus inactivation during the manufacturing steps of two intravenous immunoglobulin (IGIV) preparations. Virus inactivation and/or removal by processing steps, such as ethanol fractionation and polyethylene glycol precipitation, and deliberate virucidal steps, such as solvent/detergent treatment and pasteurization, were tested on a variety of human pathogenic and experimental model viruses, including human immunodeficiency, Hepatitis C, Mumps, Vaccinia, Chikungunya, Vesicular Stomatitis, Sindbis, and ECHO viruses. All viruses were successfully inactivated and/or eliminated by the processing steps studied. In some cases, however, multiple steps were required. We conclude that the incorporation of steps deliberately designed to inactivate or remove viruses during the production of IGIV provides an extra measure of viral safety.
Y Uemura, and
Y H Yang, and
C M Heldebrant, and
K Takechi, and
K Yokoyama
January 1989,
Vox sanguinis,
Y Uemura, and
Y H Yang, and
C M Heldebrant, and
K Takechi, and
K Yokoyama
January 1987,
Vox sanguinis,
Y Uemura, and
Y H Yang, and
C M Heldebrant, and
K Takechi, and
K Yokoyama
January 1993,
Vox sanguinis,
Y Uemura, and
Y H Yang, and
C M Heldebrant, and
K Takechi, and
K Yokoyama
January 2010,
Human antibodies,
Y Uemura, and
Y H Yang, and
C M Heldebrant, and
K Takechi, and
K Yokoyama
August 2000,
Preparative biochemistry & biotechnology,
Y Uemura, and
Y H Yang, and
C M Heldebrant, and
K Takechi, and
K Yokoyama
January 1992,
Vox sanguinis,
Y Uemura, and
Y H Yang, and
C M Heldebrant, and
K Takechi, and
K Yokoyama
June 1991,
Transfusion,
Y Uemura, and
Y H Yang, and
C M Heldebrant, and
K Takechi, and
K Yokoyama
December 2009,
Journal of applied microbiology,
Y Uemura, and
Y H Yang, and
C M Heldebrant, and
K Takechi, and
K Yokoyama
July 1996,
Frontiers in bioscience : a journal and virtual library,
Y Uemura, and
Y H Yang, and
C M Heldebrant, and
K Takechi, and
K Yokoyama
January 2017,
Biologics : targets & therapy,
